HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Citation Map Services Related articles in Hematology Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by de Leval, L. Articles by Gaulard, P. Search for Related Content PubMed PubMed Citation Articles by de Leval, L. Articles by Gaulard, P. Social Bookmarking                   What's this?

Pathobiology and Molecular Profiling of Peripheral T-Cell Lymphomas

Correspondence: Laurence de Leval, MD PhD, Département de Pathologie, CHU Sart Tilman, Tour de Pathologie, B23, +1, B- 4000 Liège, Belgium; Phone: +32 4 3662405; Fax: +32 4 3662919; e-mail: L.deLeval{at}ulg.ac.be

Abstract

Peripheral T-cell lymphomas (PTCLs) are a heterogeneous group of rare diseases, usually manifesting clinical aggressiveness. Although important novel insights into the pathobiology of nodal PTCL have been gained recently from molecular profiling studies and clinico-pathological analyses, the pathogenetic molecular lesions remain to be deciphered for most entities. Angioimmunoblastic T-cell lymphoma (AITL) comprises CD4⁺ CXCL13⁺ neoplastic cells displaying overlapping immunophenotypical and molecular features with normal follicular helper T cells. This derivation might account for the presence of a prominent non-neoplastic component in AITL tissues and the clinical manifestations of the disease reflective of an immunological dysfunction. ALK⁺ anaplastic large cell lymphoma (ALCL), defined by ALK gene translocation with various gene partners, is composed of CD30⁺ ALK⁺ cells with a cytotoxic phenotype and usually carries a good prognosis. ALK^– ALCL, now considered as a distinct disease entity, is morphologically and immunophenotypically similar to ALK⁺ ALCL, except for ALK expression, but has distinctive molecular features. PTCL, not otherwise specified (PTCL, NOS), the largest PTCL category, which is derived from activated CD4⁺ (or CD8⁺) T cells, is markedly heterogeneous, including at the molecular level. Gene expression profiling approaches have identified novel biomarkers of potential therapeutic interest, and suggest the existence of molecularly distinct PTCL, NOS subgroups.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

Related articles in Hematology:

Prognosis and Primary Therapy in Peripheral T-Cell Lymphomas

Kerry J. Savage
Hematology 2008 2008: 280-288. [Abstract] [Full Text]